期刊
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
卷 14, 期 1, 页码 88-99出版社
SPRINGER
DOI: 10.1007/s12265-020-10035-2
关键词
Immunosuppression; T-cells; Cell therapy; Xenogeneic; Heart failure; Preclinical; Animal models
资金
- European Union's Horizon 2020 research and innovation program [668724]
- Horizon2020 ERC-2016-COG EVICARE [725229]
- European Research Council (ERC) [725229] Funding Source: European Research Council (ERC)
Cell-based therapies for heart failure are being investigated, but the use of non-autologous cells presents challenges due to immune rejection responses. Adequate immunosuppressive regimens are crucial to overcome this issue, but clear guidelines are currently lacking. This review assesses the immunological barriers and provides recommendations for immunosuppressive regimens in preclinical cardiac cell-replacement studies.
Various cell-based therapies are currently investigated in an attempt to tackle the high morbidity and mortality associated with heart failure. The need for these therapies to move towards the clinic is pressing. Therefore, preclinical large animal studies that use non-autologous cells are needed to evaluate their potential. However, non-autologous cells are highly immunogenic and trigger immune rejection responses resulting in potential loss of efficacy. To overcome this issue, adequate immunosuppressive regimens are of imminent importance but clear guidelines are currently lacking. In this review, we assess the immunological barriers regarding non-autologous cell transplantation and immune modulation with immunosuppressive drugs. In addition, we provide recommendations with respect to immunosuppressive regimens in preclinical cardiac cell-replacement studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据